Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 9/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821670 | 0.88 | DPP4 (0.46) | KMT2AATMCNR1DPP4CNR2 | |
| Hydrochloric Acid SCHEMBL3819328 | 0.87 | DPP4 (0.46) | KMT2AATMCNR1DPP4CNR2 | |
| SCHEMBL3817571 | 0.86 | KMT2A (0.42) | KMT2AATMCNR1CDC7DBF4 | |
| SCHEMBL3814385 | 0.80 | DPP4 (0.40) | HSD11B1DPP4CRHR1 | |
| SCHEMBL6024731 | 0.78 | KMT2A (0.47) | KMT2AATMCNR1HSD11B1DPP4 | |
| SCHEMBL3818618 | 0.77 | TACR1 (0.45) | CNR1 | |
| SCHEMBL3822423 | 0.74 | DPP4 (0.40) | CNR1DPP4CNR2 | |
| SCHEMBL3814518 | 0.73 | DPP4 (0.37) | CNR1HSD11B1DPP4CNR2 | |
| SCHEMBL6807275 | 0.72 | CNR1 (0.46) | KMT2AATMCNR1CNR2 | |
| SCHEMBL3818189 | 0.72 | KDM1A (0.41) | KMT2ACNR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937672-B1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-7541361-B2 | N-[4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-06-02 | — | — | US | disclosed |
| US-20080176867-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-1937672-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007006928-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176867-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | NQO1, PRMT5, QDPR | KMT2A 1313/4885ATM 3985/4885CNR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.